Exit Interview: Medtronic CEO Hawkins Sees Burgeoning Challenges, Opportunities
This article was originally published in The Gray Sheet
Executive Summary
In an environment impacted by health care reform and an increasingly complex reimbursement arena, device trials must demonstrate both clinical and economic utility equally, said Bill Hawkins, who recently ended his tenure as Medtronic’s chairman and CEO.
You may also be interested in...
Medtronic Mines GE For New Chief; Omar Ishrak Starts In June
Medtronic's incoming CEO has run a similarly sized medical technology business in terms of sales for the past two years, albeit with a focus on diagnostic and monitoring tools rather than therapeutic technologies.
Fracture Data Spurs Medtronic To Suspend Sales Of Fidelis ICD Lead
Medtronic's decision to halt worldwide distribution of its Sprint Fidelis defibrillator leads has attracted congressional scrutiny of the company's response to data showing the leads were vulnerable to fracture
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.